2021
DOI: 10.1016/j.jdcr.2021.05.001
|View full text |Cite
|
Sign up to set email alerts
|

Treatment of acyclovir-resistant herpes simplex virus with intralesional cidofovir

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
5
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 7 publications
(5 citation statements)
references
References 9 publications
0
5
0
Order By: Relevance
“…While foscarnet and cidofovir are typically effective in treating acyclovir-resistant HSV infections, they are usually administered parenterally and have a risk of nephrotoxicity. 2,7,8 Topical antiviral agents such as trifluridine have been evaluated for antiviral drug resistance but have only partial activity. 2 Imiquimod is an immune response modifier that stimulates cytokine production, including interferon-alpha, enhancing cell-mediated immunity against viral infections.…”
Section: Discussionmentioning
confidence: 99%
“…While foscarnet and cidofovir are typically effective in treating acyclovir-resistant HSV infections, they are usually administered parenterally and have a risk of nephrotoxicity. 2,7,8 Topical antiviral agents such as trifluridine have been evaluated for antiviral drug resistance but have only partial activity. 2 Imiquimod is an immune response modifier that stimulates cytokine production, including interferon-alpha, enhancing cell-mediated immunity against viral infections.…”
Section: Discussionmentioning
confidence: 99%
“…Despite the limitations of small-scale studies, the literature suggests that cidofovir may be effective in both immunocompetent and immunosuppressed patients [6]. While topical cidofovir has been used more widely, studies have demonstrated that systemic and subcutaneously formulations of cidofovir are safe in patients with HIV/AIDS, lymphomas, leukemias, and those with chronic infection, including disseminated tuberculosis (Table 1) [5,14,18,19,22,[25][26][27].…”
Section: Clinical Usesmentioning
confidence: 99%
“…The first patient trialed on IL cidofovir was initially treated with six months of combined IV and IL cidofovir (15 mg/mL), followed by three months of IL-only therapy with significant regression and without evidence of HSV recurrence [14]. Four subsequent patients with extensive genital HSV have been reported in the literature who were treated with two to six rounds of 12.5 to 15 mg/mL IL cidofovir, with near resolution being documented as soon as two weeks following the treatment and resolution as early as six weeks [22,[25][26][27]. One patient with a hypertrophic anal lesion was treated with a combination of IL cidofovir and imiquimod 5% cream, and saw no evidence of recurrence three months following treatment [26].…”
Section: Herpes Simplex Virusmentioning
confidence: 99%
“…It also demonstrates in-vitro activity against several DNA viruses like herpesvirus, poxvirus, polyomavirus, and papillomavirus (de Clercq, 2003). It is used off-label in respiratory papillomatosis (Ballestas et al, 2021), acyclovir-resistant herpes simplex virus (Enescu et al, 2021), skin lesions associated with herpesvirus (Ferrer et al, 2021), BK polyomavirus (Napolitano et al, 2021). We have thus built upon the existing bibliometric analyses pertaining to mpox virus disease (Cheng et al, 2022;Zeeshan et al, 2022).…”
Section: Bibliometric Analysismentioning
confidence: 99%